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Abstract Fingolimod was the first oral drug approved for
multiple sclerosis treatment. Its principal mechanism of action
is blocking of lymphocyte trafficking. In addition, recent stud-
ies have shown its capability to diminish microglia activation.
The effect of preventive and curative fingolimod treatment on
the time-course of neuroinflammation was investigated in the
experimental autoimmune encephalomyelitis rat model for
multiple sclerosis. Neuroinflammatory progression was
followed in Dark Agouti female rats after immunization.
Positron-Emission tomography (PET) imaging with
(R)-[11C]PK11195 was performed on day 11, 15, 19, 27, 29
and 34 during normal disease progression, preventive and
curative treatments with fingolimod (1 mg/kg/day).
Additionally, bodyweight and clinical symptoms were deter-
mined. Preventive treatment diminished bodyweight loss and
inhibited the appearance of neurological symptoms. In non-
treated rats, PET showed that neuroinflammation peaked in
the brainstem at day 19, whereas the imaging signal was de-
creased in cortical regions. Both preventive and curative treat-
ment reduced neuroinflammation in the brainstem at day 19.
Eight days after treatment withdrawal, neuroinflammation had
flared-up, especially in cortical regions. Preventive treatment
with fingolimod suppressed clinical symptoms and neuroin-
flammation in the brainstem. After treatment withdrawal, clin-
ical symptoms reappeared together with neuroinflammation in
cortical regions, suggesting a different pathway of disease
progression.
Keywords Fingolimod .Multiple sclerosis . Experimental
autoimmune encephalomyelitis . Positron-emission
tomography . Neuroinflammation
Introduction
Multiple sclerosis (MS) is an inflammatory and degenerative
disease of the central nervous system characterized by demy-
elination. New therapies for MS have focused on suppression
of relapses, and the reduction of lesions observed by magnetic
resonance imaging (MRI). Fingolimod (FTY720; Gilenya®)
was the first oral agent to be approved for treatment of MS.
Results from clinical trials have consistently proved an effec-
tive decrease in relapse rates, new MRI lesions, disability
progression and brain volume loss in patients with relapsing-
remitting MS (Cohen et al. 2010; Kappos et al. 2010;
Calabresi et al. 2014).
Fingolimod is a sphingosine-1-phosphate (S1P) analogue
that is phosphorylated in vivo and binds as a functional antag-
onist to all the S1P receptor subtypes, except S1P2 (Brinkmann
et al. 2002; Cohen and Chun 2011). The S1P receptors are
present on lymphocytes and play a key role in lymphocyte
trafficking (Graeler and Goetzl 2002, 2004; Lo et al. 2005).
Fingolimod’s mechanism of action in MS is not known
with certainty. However, fingolimod was shown to inhibit
egress of lymphocytes from lymph nodes, thus preventing
their recirculation and brain infiltration and the onset of an
autoimmune reaction (Cohen and Chun 2011). Fingolimod
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can also penetrate the blood brain barrier (BBB) and bind to
neurons, oligodendrocyte progenitor cells, astrocytes and mi-
croglia (Foster et al. 2007; Jeffery 2013). Fingolimod has re-
cently been shown to suppress microglia activation in vitro
(Coelho et al. 2007; Jackson et al. 2011; Noda et al. 2013;
Cipriani et al. 2015) and in vivo inMSmodels (Anthony et al.
2014; Airas et al. 2015). This suggests that a combination of
beneficial anti-inflammatory, neuroprotective and reparative
effects may contribute to the efficacy of fingolimod in MS.
Microglia activation, a hallmark of neuroinflammation, is
accompanied by increased expression of the 18-kDa
translocator protein (TSPO), formerly known as the peripheral
benzodiazepine receptor (Papadopoulos et al. 2006). This in-
crease in TSPO expression can be visualized by positron-
emission tomography (PET) with the tracer (R)-[11C]
PK11195, as shown previously in animal models
(Vowinckel et al. 1997; Abourbeh et al. 2012; Xie et al.
2012; Mattner et al. 2013; de Paula Faria et al. 2014a, b;
Airas et al. 2015) and patients (Debruyne et al. 2003;
Versijpt et al. 2005; Oh et al. 2011; Politis et al. 2012;
Takano et al. 2013; Colasanti et al. 2014; Rissanen et al.
2014; Park et al. 2015; Giannetti et al. 2015).
The aim of this study was to evaluate how microglia acti-
vation is affected by fingolimod when the treatment was
started before or after the appearance of the symptoms. To
study this effect, repetitive (R)-[11C]PK11195 PETscans were




Adult female Dark Agouti rats (n = 28) at 8–10 weeks of age
(153 ± 7 g) were obtained from Janvier (France). After arrival,
the rats were allowed to acclimatize for at least 7 days. During
the entire study, the rats were housed in pairs in Makrolon
cages on a layer of wood shavings, in a room at constant
temperature (21 ± 2 °C) and 12 h day/night periods.
Commercial chow and water were available ad libitum.
All animal experiments were performed according to the
Dutch Law on Animal Welfare and were approved by the
Institutional Animal Care and Use Committee of the
University of Groningen (DEC 6480B).
Experimental Model
EAE was induced according to the previously described proto-
col (Ledeboer et al. 2003; de Paula Faria et al. 2014b). Briefly,
rats were anesthetized with 5% isoflurane (mixed with medical
air) and immunized intradermal, at both sides of the dorsal tail
base, with 25 μg of endotoxin-free rat recombinant myelin
oligodendrocyte glycoprotein1–125 (Tebu-bio) dissolved in
100 μL of 25 mM sodium acetate pH 4.0 and emulsified in
100 μL of Incomplete Freund’s Adjuvant (Difco Lab).
Bodyweight and clinical symptoms were evaluated daily
by the same researcher. Symptoms were scored as: 0, no clin-
ical symptoms; 0.5, limp distal tail; 1, completely limp tail; 2,
ataxia; 3, moderate paraparesis; 3.5 unilateral hind-limb paral-
ysis; 4, bilateral hind-limb paralysis; 5, bilateral hind-limb
paralysis and bladder paralysis; and 6, moribund or dead.
Water and powder food were provided by hand to those rats
suffering paralysis. If needed, subcutaneous injections (1–2
times) of saline were given daily. Moribund rats with a score
of 6 were terminated, and were included in the analysis with a
score of 6 until the end of the experiment.
Study Design
The distribution of rats during the study is detailed in Table S1.
Three groups were defined: a non-treated control group (n = 8),
and a preventive (n = 10) and a curative treatment (n = 10)
group. Fingolimod was administered daily to the treatment
groups by orogastric gavage, which was shown to have no
effect in corticosterone levels, body weight or food consump-
tion (Turner et al. 2012). The rats were trained to receive the
oral gavage with water (5 ml/kg) from day 5 to 7. The non-
treated group received water instead of treatment until day 19,
when these rats were terminated. The preventive treatment
group received the drug from day 8 until day 26, while the
curative treatment group was treated from day 15 (after the
PET scan) until day 26. The treatment consisted of 1 mg/kg
of fingolimod dissolved in 5 ml/kg of water. In both treatment
groups, drug administration was stopped at day 27 and the rats
were terminated after the last PET scan on day 34. A visual
representation of the study design can be found in Fig. 1.
PETAcquisition and Reconstruction
The synthesis of (R)-[11C]PK11195 was reported in detail else-
where (Doorduin et al. 2009). Further details on the injected
activity and mass can be found in Table 1. PET scans were
performed with a microPET Focus 220 camera (Siemens
Medical Solutions, USA) at day 11, 15, 19, 27, 29, and 34 after
immunization. The first three scans were defined to monitor:
initial symptoms (10–12 days), the first (14–15 days), and the
second (19–20 days) relapse of symptoms, according to previ-
ous results (de Paula Faria et al. 2014b). The scan at day 27 was
intended to reflect the neuroinflammatory situation at the end of
treatment, and the last two scans (29 and 34 days) were defined
to demonstrate the effects of treatment withdrawal.
Before each scan, the rats were anesthetized with 5%
isoflurane mixed with oxygen (0.8 ml/min flow), and remained
anesthetized with 1.5–2% isoflurane until the end of the scan.
The tail vein was cannulated for tracer injection. The injected
(R)-[11C]PK11195 dose was 46 ± 22 MBq, with an injected
mass of 0.49 ± 0.39 nmol (no statistical differences between
groups). About 40min after tracer injection, the rats were placed
into the camera in a prone position with the head in the field of
view. At 45 min after tracer injection, a 30-min emission scan
was started. A transmission scan of 515 s was obtained using a
57Co point source for attenuation and scatter correction.
List-mode data was reconstructed into a single frame
(OSEM2D, 4 iterations and 16 subsets) after being normalized
and corrected for attenuation, scatter and decay. Final images
had a 256 × 256 × 95 matrix with a pixel width of 0.63 mm
and a slice thickness of 0.79 mm. Standardized uptake value
(SUV) images were constructed for all the scans, defined as:
radioactivity concentration (MBq/cm3)/[injected dose (MBq)/
body weight (g)].
Image Registration
After reconstruction, PET images were processed with PMOD
v3.6 (PMOD Technologies, Switzerland). A tracer-specific
(R)-[11C]PK11195 template was constructed following the
methodology described previously (Vállez García et al.
2015), using healthy female Dark Agouti rats (n = 12, weight
166 ± 11 g, 9–12 weeks old) (de Paula Faria et al. 2014b). The
template was used as reference in the automatic rigid registra-
tion procedure. Volumes of interest (VOI) were defined based
on previously constructed regions (Vállez García et al. 2015)
for the right and left hemisphere, including the amygdala,
brainstem, cerebellum, cortex, globus pallidum, hippocam-
pus, hypothalamus, midbrain, septum, striatum and thalamus.
Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics
20, and the results are presented asmean ± standard error (SE).
The Generalized Estimating Equations (GEE) model (Hardin
and Hilbe 2012) was used to account for the repeated mea-
surements in the longitudinal design, and the missing data.
The exchangeable correlation matrix was selected for the anal-
ysis, and the Wald test used to report p-values, which were
considered statistically significant at p < 0.05 without correc-
tion for multiple comparisons.
Table 1 Injected dose and
injected mass of (R)-
[11C]PK11195
Scan Group Injected dose (MBq) Injected mass (nmol)
Mean ± SD Mean ± SD
day 11 No treatment 37 ± 29 0.43 ± 0.48
Preventive treatment 58 ± 15 0.53 ± 0.41
Curative treatment 59 ± 18 0.33 ± 0.11
day 15 No treatment 42 ± 28 0.17 ± 0.18
Preventive treatment 47 ± 19 0.57 ± 0.61
Curative treatment 32 ± 14 0.67 ± 0.49
day 19 No treatment 52 ± 37 0.46 ± 0.20
Preventive treatment 54 ± 31 0.86 ± 0.61
Curative treatment 39 ± 25 0.52 ± 0.26
day 27 Preventive treatment 33 ± 19 0.52 ± 0.48
Curative treatment 38 ± 24 0.45 ± 0.45
day 29 Preventive treatment 46 ± 17 0.36 ± 0.16
Curative treatment 48 ± 15 0.36 ± 0.15
day 34 Preventive treatment 54 ± 9 0.53 ± 0.31








Fig. 1 Study design. The rats were trained to receive oral gavage with
water (5 ml/kg) from day 5 to 7. The non-treated group (n = 8) continued
with administration of water from day 8 until day 19, when the rats where
terminated. The preventive group (n = 10) received a treatment with
fingolimod (1 mg/kg dissolved in 5 ml/kg of water) from day 8 until
day 26, while the curative group (n = 10) received water from day 8 to
14, and the fingolimod treatment from day 15 until day 26. At day 27, the
treatment was stopped for the preventive and curative group, and at day
34 the rats were terminated
Gain in BodyWeight The gain in bodyweight was calculated
for each rat as the difference between the body weights minus
the weight on the immunization day. For the statistical model,
the ‘group’ and ‘day of the measurement’ were included as
variables.
Clinical Symptoms The clinical scores were analyzed includ-
ing ‘group’ and the ‘day of the measurement’ as variables of
interest in the model.
VOI-Based Analysis An independent GEE model was creat-
ed for each of the predefined VOIs, including the
(R)-[11C]PK11195 uptake (SUV) as the outcome variable,
and the variables ‘group’, ‘scan’, and its interaction as predic-
tor terms in the model.
Voxel-Based Analysis The SPM12 software (University
College London, United Kingdom), in combination with
SwE v1.2.2 (Guillaume et al. 2014) and SAMIT v1.2
(Vállez García et al. 2015), was used for the voxel-based anal-
ysis. PET images were smoothed using a 1.2 mm Gaussian
kernel. Corrections for small sample size (‘type C2’) and es-
timation of the degrees of freedom (‘approximate III’) were
included in the design. The variables ‘group’, ‘scan’, ‘clinical
score’, and their interactions, were included in the statistical
model. The level of significance was set to a high threshold of
p-uncorrected = 0.02275 (Z-score = 2, α = 0.05, one-tailed
hypothesis), and an extent threshold of 100 voxels (voxel size
of 0.2 × 0.2 × 0.2 mm).
Results
Gain in Bodyweight
A statistically significant difference on the gain in body
weight was observed between groups (p = 0.009). In the
pairwise group comparison, the ‘estimated marginal mean’
(EMM) on the gain in body weight of the curative treatment
(8.2 ± 13.7 g) was not statistically different than the gain in the
non-treated group (7.1 ± 13.4 g). However, the preventive
treatment group showed an statistically significant higher gain
of body weight (13.1 ± 12.6 g, p = 0.007) when compared
with the non-treated group, and the curative group (p = 0.019)
(Table 2; Fig. 2).
Clinical Symptoms
A statistically significant difference on the clinical score was
found between groups (p < 0.001). In the pairwise compari-
son, the clinical score of the curative group (EMM = 0.7 ± 2.4)
was not statistically different than the one found in the non-
Table 2 Statistical comparison of the gain in bodyweight between
groups, using the Generalized Estimating Equations model
B SE 95% Wald CI p-value
Lower Upper
(Intercept) −0.38 1.96 −4.21 3.46 0.847
Preventive treatment 5.98 2.24 1.60 10.37 0.007
Curative treatment 1.11 2.48 −3.75 5.97 0.654
Day 0.50 0.09 0.33 0.66 <0.001
The parameter estimates were obtained using the no-treatment group as
reference category
























Fig. 2 Gain in body weight over the study (mean ± SE). From left to right, the vertical dotted lines represent: the start of treatment in the preventive
group (day 8), the start of treatment of curative group (day 15), and the last day of treatment (day 26)
treated group (EMM = 0.7 ± 2.3). While the preventive treat-
ment group showed a statistically significant lower clinical
score (EMM = 0.1 ± 2.2) than the non-treated group
(p < 0.001) and the curative treatment group (p = 0.021)
(Table 3; Fig. 3).
VOI-Based Analysis
VOI-based analysis of (R)-[11C]PK11195 PET scans revealed
a statistically significant difference between groups in the
brainstem (p = 0.024) and cortical (p = 0.030) regions. No
other overall differences were found between groups in any
of the other brain regions. When explored in more detail, a
statistically significant lower tracer uptake was found in the
brainstem in the preventive treatment group (EMM
= 0.48 ± 0.01, p = 0.023), but not in the curative treatment
group (EMM = 0.53 ± 0.03), as compared with the uptake in
the non-treated group (EMM = 0.62 ± 0.06). In addition, a
statistically significant higher (R)-[11C]PK11195 uptake was
found in the cortex of the preventive treatment group
(EMM = 0.43 ± 0.01, p = 0.004) when compared with the
non-treated group (EMM = 0.38 ± 0.01). However, no statis-
tical difference with the other groups was observed for the
curative treatment group (EMM = 0.40 ± 0.01) in the cortical
region. Based on these results, a more detailed exploration of
the data was performed for the brainstem and cortex region
(Table 4, and Fig. 4).
Brainstem Region In the brainstem region (Fig. 4, left), the
within-group exploration of the VOI-based results showed
that the non-treated group had a statistically significant in-
crease of (R)-[11C]PK11195 uptake on day 19 as compared
to day 15 (p = 0.002) and day 11 (p = 0.001). Moreover, the
preventive treatment group showed a statistically significant
higher uptake at day 34, when compared to day 19 (p = 0.018),
at day 15 when compared to day 19 (p < 0.001) and day 29
(p = 0.041). Finally, the curative treatment group showed a
higher uptake at day 19 (p = 0.006), day 29 (p = 0.028), and
day 34 (p = 0.033) when compared to day 11; and a higher
uptake at day 34 than at day 27 (p = 0.017).
In addition, in a between-groups comparison, only statisti-
cally significant differences were observed between the differ-
ent treatment regimens on day 19. Preventive treatment result-
ed in lower tracer uptake than the curative treatment
(p = 0.017). And both, the preventive and curative treatment
groups, exhibited a lower tracer uptake in the brainstem than
the non-treated group (p = 0.001 and p = 0.036 respectively).
Cortical Region In the cortical region (Fig. 4, right), for the
within-group comparison, a statistically significant decrease




















Fig. 3 Clinical symptoms score (mean ± SE). From left to right the vertical lines represent: the start of treatment in the preventive group (day 8), the start
of treatment of curative group (day 15), and the last day of treatment (day 26)
Table 3 Statistical comparison of the clinical symptoms, using the
Generalized Estimating Equations model
B SE 95% Wald CI p-value
Lower Upper
(Intercept) −0.07 0.15 −0.37 0.22 0.635
Preventive treatment −0.59 0.15 −0.89 −0.30 <0.001
Curative treatment 0.03 0.21 −0.38 0.43 0.895
Day 0.05 0.01 0.02 0.08 0.001
The parameter estimates were obtained using the saline group as reference
category
B Unstandardized coefficient; SE Standard error; CI Confidence interval
treated group at day 19 (p = 0.029) when compared to day 11.
In the preventive treatment group, an increased uptake was
found at day 34 when compared to day 15 (p = 0.037) and
day 19 (p = 0.041). In the curative treatment group, a decrease
in the uptake was found at day 27 (p = 0.033) and day 29
(p = 0.024) when compared to day 11. In addition, an in-
creased uptake was observed in the curative group at day 34
when compared to day 19 (p = 0.043), day 27 (p = 0.002), and
day 29 (p < 0.001).
Moreover, between-group comparison revealed a signifi-
cantly lower uptake in the non-treated group at day 19 as
compared with preventive (p = 0.032), but not with the cura-
tive treated rats (p = 0.070). Additionally, a statistically sig-
nificant higher uptake was also found at day 29 in the preven-
tive group compared with the curative treatment group
(p = 0.014).
Voxel-Based Analysis
Exploration of the results by voxel-based analysis (Fig. 5;
Table S2) was restricted to the group comparisons at day 19
(based on previous results of the VOI-based analysis) and to
the corre la t ion between the cl in ica l scores and
(R)-[11C]PK11195 uptake.
Day 19 Statically significant increased uptake was found most-
ly in the brainstem and cerebellum of the non-treated group
when compared to the preventive treatment group, but not
when compared to curative treatment group. At the same time,
a decreased (R)-[11C]PK11195 uptake was found in in the cor-
tical region and the striatum of the non-treated group when
compared to the preventive and the curative treatment groups.
When both treatment groups were compared, an increased
Table 4 (R)-[11C]PK11195 PET uptake in the brainstem and cortex. These regions showed an overall statistically significant difference between
groups (p < 0.05) in the Generalized Estimating Equations model
Day 11 Day 15 Day 19 Day 27 Day 29 Day 34
Mean ± SE Mean ± SE Mean ± SE Mean ± SE Mean ± SE Mean ± SE
Brainstem No treatment 0.46 ± 0.02 0.55 ± 0.08 0.85 ± 0.12
Preventive 0.48 ± 0.04 0.52 ± 0.01 0.45 ± 0.02 0.48 ± 0.02 0.47 ± 0.02 0.50 ± 0.01
Curative 0.46 ± 0.02 0.59 ± 0.09 0.58 ± 0.05 0.49 ± 0.03 0.50 ± 0.02 0.60 ± 0.06
Cortex No treatment 0.41 ± 0.02 0.38 ± 0.02 0.35 ± 0.01
Preventive 0.42 ± 0.03 0.42 ± 0.02 0.40 ± 0.02 0.41 ± 0.03 0.45 ± 0.02 0.46 ± 0.02
Curative 0.42 ± 0.01 0.41 ± 0.02 0.40 ± 0.02 0.37 ± 0.02 0.38 ± 0.02 0.44 ± 0.01
Only those regions with statistical significant differences are included
SE Standard error





















































Fig. 4 (R)-[11C]PK11195 PET uptake (mean ± SE) in the brainstem (left) and in the cerebral cortex (right). Both regions revealed a statistically
significant difference between groups in the overall analysis
Preventive treatment
Positive correlation Negative correlation
a  Increased (R)-[11C]PK11195 uptake in non-treated group vs.
Curative treatment
b  Decreased (R)-[11C]PK11195 uptake in non-treated group vs.
Preventive treatment Curative treatment
c  Increased (R)-[11C]PK11195 uptake in curative treatment vs.
Preventive treatment
d  Correlation between (R)-[11C]PK11195 and clinical symptoms
Lorem ipsum
Fig. 5 Maximum intensity projection (i.e. ‘glass-brain’ display) of the
voxel-based analysis. At day 19, regions with a statistically significant a
increase and b decrease of (R)-[11C]PK11195 uptake in the non-treated
group when compared with the preventive (left panels) and curative (right
panels) treatment groups. c At day 19, regions with a statistically
significant increase of (R)-[11C]PK11195 uptake in the curative treatment
group when compared with the preventive group. d Correlation of the
clinical score with the (R)-[11C]PK11195 PET uptake, including all time
points and groups
(R)-[11C]PK11195 uptake was found, mostly located in the
brainstem, midbrain, striatum, and thalamus of the curative
treatment group as compared to the preventive treatment group.
Clinical Symptoms The clinical score showed a strong statis-
tical correlation with the (R)-[11C]PK11195 uptake, with a
positive correlation in the brainstem, cortex, hippocampus,
septum, striatum, and thalamus; and a negative correlation in
most of the cortex and cerebellum.
Discussion
In the present study, EAE rats were monitored for disease
progression and fingolimod treatment effects. Differences in
the bodyweight gain were observed between groups, with a
significant decrease in bodyweight in those animals present-
ing clinical symptoms. This effect can be explained by
inflammatory-induced cachexia, a common process in all the
EAE models, an effect observed also previously by our group
(de Paula Faria et al. 2014b). In this respect, fingolimod ap-
pears to improve the animals’ wellbeing, supporting the evi-
dence of an immune-modulatory action of the drug, e.g. by
preventing lymphocytes to exit the lymph nodes and thus to
infiltrate into the brain (Cohen and Chun 2011), and by sup-
pressing microglia activation via p38 mitogen-activated pro-
tein kinases (Cipriani et al. 2015).
The brainstem seems to be the most affected brain region in
the EAE rat model, with a progressive increase in
(R)-[11C]PK11195 uptake (neuroinflammation) over time.
These results are in agreement with those published previous-
ly by de Paula Faria et al. (de Paula et al. 2014b), where the
increased (R)-[11C]PK11195 uptake in the brainstem was con-
firmed by Iba1 immunohistochemistry, demonstrating the
presence of activated microglia and/or macrophages in this
region. The treatment with fingolimod resulted in a clear de-
crease in the neuroinflammation in the brainstem, as demon-
strated by a reduction in the (R)-[11C]PK11195 uptake detect-
ed with the PETcamera. In those rats where the treatment was
started before the onset of the symptoms (preventive treat-
ment) the benefits of fingolimod were superior to those ob-
tained in rats where the drug was administered when the initial
symptoms were already present.
In the present study, the neuroinflammatory process was
clearly manifest in the non-treated animals at day 19. This
inflammatory process was significantly reduced with the ad-
ministration of fingolimod (1 mg/kg per day). This effect was
significantly stronger in the preventive treatment group, in
which fingolimod was administered before the appearance
of the first clinical symptoms, than in the curative treatment
group, where the administration of the drug was delayed until
the first relapse of the symptoms at day 15. Moreover, no
evidence of the disease was detected in the animals following
the preventive regimen during the whole period in which the
animals were receiving the drug, neither according to the
(R)-[11C]PK11195 uptake detected by the PET camera nor
according to the manifestation of clinical symptoms related
with EAE disease progression. In the curative treatment
group, on the other hand, the drug could partly reduce the
existing symptoms, but was not capable to completely cure
all symptoms that were already present. Consequently, some
symptoms remained present for the rest of the study. In line
with this observation, curative administration of the drug
fingolimod partially extinguished the initial neuroin
flammatory process in the brainstem that had started during
the period before fingolimod treatment (from day 8 to 15). The
statistically significant difference in tracer uptake between the
preventive and the curative treatment group at day 19 was not
present anymore at day 27 (end of treatment), as the levels of
(R)-[11C]PK11195 uptake in the brainstem of curatively treat-
ed animals went back to those detected during the first scan on
day 11. These data suggest that fingolimod needs few days to
quench neuroinflammation and thus delay disease progres-
sion, but it could not completely reverse already existing
damage.
Interestingly, clinical symptoms seem to positively corre-
late with (R)-[11C]PK11195 uptake in the brainstem, globus
pallidum, hippocampus, thalamus and septum. A negative
correla t ion between cl inical symptoms and (R) -
[11C]PK11195 uptake was also observed in part of the cortex
and cerebellum. The positive correlation between
(R)-[11C]PK11195 uptake in several brain regions and the
clinical score likely reflects the ongoing neuroinflammatory
process caused by the EAE disease progression, while the
negative correlation may be explained by the migration of
microglia from cortical regions to sites of neuroinflammation
in the brainstem and midbrain. This migration of microglia
seems to be reflected at day 19 in the statistical lower
(R)-[11C]PK11195 signal observed in the cortical region of
non-treated group, when compared with the preventive and
the curative treatments, a result observed both in the voxel-
based and in the VOI-based analysis. This migratory hypoth-
esis, however, requires further investigation.
Preventive treatment with fingolimod suppressed the man-
ifestation of clinical symptoms and neuroinflammation in the
brainstem, while curative treatment was able to partly reduce
the consequences of EAE. After removal of the treatment,
clinical symptoms started to (re)appear, but these symptoms
were less severe than those observed in the non-treated group
(day 11–19). This process was accompanied by neuroinflam-
mation, not only in the brainstem but also in cortical regions.
These results are consistent with lymphocytes leaving the
lymph nodes and returning to circulation. Interestingly, the
cortical neuroinflammation was not observed in non-treated
EAE rats, suggesting a different disease progression pattern
after withdrawal of fingolimod treatment. However, it remains
unclear how fingolimod could have affected the neuroinflam-
mation pattern after withdrawal of the drug.
In summary, preventive treatment with fingolimod is able
to suppress the manifestation of clinical symptoms and the
associated neuroinflammatory process that takes place in the
brainstem of EAE rats, while the curative treatment could
reduce neuroinflammation and moderate, but not fully re-
verse, the symptoms in this MS model. After removal of the
treatment, the clinical symptoms started to (re)appear and
were accompanied by neuroinflammation in cortical regions,
suggesting a different mode of disease progression after with-
drawal from fingolimod treatment.
Acknowledgements The present study was supported by Novartis
Pharma AG.
Compliance with Ethical Standards
Conflict of Interest The authors declare no conflicts of interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
Abourbeh G, Thézé B, Maroy R et al (2012) Imaging microglial/
macrophage activation in spinal cords of experimental autoimmune
encephalomyelitis rats by positron emission tomography using the
mitochondrial 18 kDa translocator protein Radioligand [18F]DPA-
714. J Neurosci 32:5728–5736. doi:10.1523/JNEUROSCI.2900-
11.2012
Airas L, Dickens AM, Elo P et al (2015) In vivo PET imaging demon-
strates diminished microglial activation after fingolimod treatment
in an animal model of multiple sclerosis. J Nucl Med 56:305–310.
doi:10.2967/jnumed.114.149955
Anthony DC, Sibson NR, Losey P et al (2014) Investigation of immune
and CNS-mediated effects of fingolimod in the focal delayed-type
hypersensitivity multiple sclerosis model. Neuropharmacology 79:
534–541. doi:10.1016/j.neuropharm.2013.12.022
Brinkmann V, Davis MD, Heise CE et al (2002) The immune modulator
FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem
277:21453–21457. doi:10.1074/jbc.C200176200
Calabresi PA, Radue E-W, Goodin D et al (2014) Safety and efficacy of
fingolimod in patients with relapsing-remitting multiple sclerosis
(FREEDOMS II): a double-blind, randomised, placebo-controlled,
phase 3 trial. Lancet Neurol 13:545–556. doi:10.1016/S1474-4422
(14)70049-3
Cipriani R, Chara JC, Rodríguez-Antigüedad A, Matute C (2015)
FTY720 attenuates excitotoxicity and neuroinflammation. J
Neuroinflammation 12:86. doi:10.1186/s12974-015-0308-6
Coelho RP, Payne SG, Bittman R et al (2007) The immunomodulator
FTY720 has a direct cytoprotective effect in oligodendrocyte progeni-
tors. J Pharmacol Exp Ther 323:626–635. doi:10.1124/jpet.107.123927
Cohen JA, Chun J (2011) Mechanisms of fingolimod’s efficacy and ad-
verse effects in multiple sclerosis. Ann Neurol 69:759–777.
doi:10.1002/ana.22426
Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramus-
cular interferon for relapsing multiple sclerosis. N Engl J Med 362:
402–415. doi:10.1056/NEJMoa0907839
Colasanti A, Guo Q, Muhlert N et al (2014) In vivo assessment of brain
white matter inflammation in multiple sclerosis with (18)F-PBR111
PET. J Nucl Med 55:1112–1118. doi:10.2967/jnumed.113.135129
de Paula Faria D, de Vries EFJ, Sijbesma JWA et al (2014a) PET imaging
of glucose metabolism, neuroinflammation and demyelination in the
lysolecithin rat model for multiple sclerosis. Mult Scler 20:1443–
1452. doi: 10.1177/1352458514526941
de Paula Faria D, Vlaming MLH, Copray SCVM et al (2014b) PET
imaging of disease progression and treatment effects in the experi-
mental autoimmune encephalomyelitis rat model. J Nucl Med 55:
1330–1335. doi: 10.2967/jnumed.114.137216
Debruyne JC, Versijpt J, Van Laere KJ et al (2003) PET visualization of
microglia in multiple sclerosis patients using [11C]PK11195. Eur J
Neurol 10:257–264. doi:10.1046/j.1468-1331.2003.00571.x
Doorduin J, Klein HC, Dierckx RA et al (2009) [11C]-DPA-713 and
[18F]-DPA-714 as new PET tracers for TSPO: a comparison with
[11C]-(R)-PK11195 in a rat model of herpes encephalitis. Mol
Imaging Biol 11:386–398. doi:10.1007/s11307-009-0211-6
Foster CA, Howard LM, Schweitzer A et al (2007) Brain penetration of
the oral immunomodulatory drug FTY720 and its phosphorylation
in the central nervous system during experimental autoimmune en-
cephalomyelitis: consequences for mode of action in multiple scle-
rosis. J Pharmacol Exp Ther 323:469–475. doi:10.1124
/jpet.107.127183
Giannetti P, Politis M, Su P et al (2015) Increased PK11195-PET binding
in normal-appearing white matter in clinically isolated syndrome.
Brain 138:110–119. doi:10.1093/brain/awu331
Graeler MH, Goetzl EJ (2002) Activation-regulated expression and che-
motactic function of sphingosine 1-phosphate receptors in mouse
splenic T cells. FASEB J 16:1874–1878. doi:10.1096/fj.02-0548com
Graeler MH, Goetzl EJ (2004) The immunosuppressant FTY720 down-
regulates sphingosine 1-phosphate G-protein-coupled receptors.
FASEB J 18:551–553. doi:10.1096/fj.03-0910fje
Guillaume B, Hua X, Thompson PM et al (2014) Fast and accu-
rate modelling of longitudinal and repeated measures neuro-
imaging data. NeuroImage 94:287–302. doi:10.1016/j.
neuroimage.2014.03.029
Hardin JW, Hilbe JM (2012). Generalized Estimating Equations, Second
edition. Chapman & Hall/CRC, Boca Raton
Jackson SJ, Giovannoni G, Baker D (2011) Fingolimod modulates
microglial activation to augment markers of remyelination. J
Neuroinflammation 8:76. doi:10.1186/1742-2094-8-76
Jeffery DR (2013) Recent advances in treating multiple sclerosis: effica-
cy, risks and place in therapy. Ther Adv Chronic Dis 4:45–51.
doi:10.1177/2040622312466279
Kappos L, Radue E-W, O’Connor P et al (2010) A placebo-controlled
trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med
362:387–401. doi:10.1056/NEJMoa0909494
Ledeboer A, Wierinckx A, Bol JGJM et al (2003) Regional and temporal
expression patterns of interleukin-10, interleukin-10 receptor and ad-
hesion molecules in the rat spinal cord during chronic relapsing EAE.
J Neuroimmunol 136:94–103. doi:10.1016/S0165-5728(03)00031-6
Lo CG, Xu Y, Proia RL, Cyster JG (2005) Cyclical modulation of
sphingosine-1-phosphate receptor 1 surface expression during lym-
phocyte recirculation and relationship to lymphoid organ transit. J
Exp Med 201:291–301. doi:10.1084/jem.20041509
Mattner F, Staykova M, Berghofer P et al (2013) Central nervous system
expression and PET imaging of the translocator protein in relapsing-
remitting experimental autoimmune encephalomyelitis. J Nucl Med
54:291–298. doi:10.2967/jnumed.112.108894
Noda H, Takeuchi H, Mizuno T, Suzumura A (2013) Fingolimod phos-
phate promotes the neuroprotective effects of microglia. J
Neuroimmunol 256:13–18. doi:10.1016/j.jneuroim.2012.12.005
Oh U, Fujita M, Ikonomidou VN et al (2011) Translocator protein PET
imaging for glial activation in multiple sclerosis. J NeuroImmune
Pharmacol 6:354–361. doi:10.1007/s11481-010-9243-6
Papadopoulos V, BaraldiM, Guilarte TR et al (2006) Translocator protein
(18kDa): new nomenclature for the peripheral-type benzodiazepine
receptor based on its structure and molecular function. Trends
Pharmacol Sci 27:402–409. doi:10.1016/j.tips.2006.06.005
Park E, Gallezot JD, Delgadillo A et al (2015) 11C-PBR28 imaging in
multiple sclerosis patients and healthy controls: test-retest repro-
ducibility and focal visualization of active white matter areas. Eur
J Nucl Med Mol Imaging 42:1081–1092. doi:10.1007/s00259-
015-3043-4
Politis M, Giannetti P, Su P et al (2012) Increased PK11195 PET binding
in the cortex of patients with MS correlates with disability.
Neurology 79:523–530. doi:10.1212/WNL.0b013e3182635645
Rissanen E, Tuisku J, Rokka J et al (2014) In vivo detection of diffuse
inflammation in secondary progressive multiple sclerosis using PET
imaging and the Radioligand C-11-PK11195. J Nucl Med 55:939–
944. doi:10.2967/jnumed.113.131698
Takano A, Piehl F, Hillert J et al (2013) In vivo TSPO imaging in patients
with multiple sclerosis: a brain PET study with [18F]FEDAA1106.
EJNMMI Res 3:30. doi:10.1186/2191-219x-3-30
Turner PV, Vaughn E, Sunohara-Neilson J et al (2012) Oral gavage in
rats: animal welfare evaluation. J AmAssoc Lab Anim Sci 51:25–30
Vállez García D, Casteels C, Schwarz AJ et al (2015) A standardized
method for the construction of tracer specific PET and SPECT rat
brain templates: validation and implementation of a toolbox. PLoS
One 10:e0122363. doi:10.1371/journal.pone.0122363
Versijpt J, Debruyne J, Van Laere K et al (2005) Microglial imaging with
positron emission tomography and atrophy measurements with
magnetic resonance imaging in multiple sclerosis: a correlative
study. Mult Scler 11:127–134. doi:10.1191/1352458505ms1140oa
Vowinckel E, Reutens D, Becher B et al (1997) PK11195 binding to the
peripheral benzodiazepine receptor as a marker of microglia activa-
tion in multiple sclerosis and experimental autoimmune encephalo-
myelitis. J Neurosci Res 50:345–353. doi:10.1002/(SICI)1097-4547
(19971015)50:2<345::AID-JNR22>3.0.CO;2-5
Xie L, Yamasaki T, Ichimaru N et al (2012) [11C]DAC-PET for noninva-
sively monitoring neuroinflammation and immunosuppressive therapy
efficacy in rat experimental autoimmune encephalomyelitis model. J
NeuroImmune Pharmacol 7:231–242. doi:10.1007/s11481-011-9322-3
